Skip to main content
. 2013 Sep 16;4(10):1729–1736. doi: 10.18632/oncotarget.1412

Figure 2. Low dose decitabine impairs growth potentialin vitro and is superior to AGI-5198 in reducing proliferative capacity.

Figure 2

A, Results from anchorage-independent growth assays using soft agar. Effect of DAC on IDH mutant TS603 and IDH wild-type TS667 cells. Cells were treated with 200nM DAC. All experiments done in triplicate. Data shown is mean +/− 1 standard deviation. B, Cell growth curves showing that DAC treatment (200nM) decreases the proliferation of TS603. C, Effects of DAC (200nM) + AGI-5198 (1uM). The anti-proliferative effects observed with DAC alone were the same as with the combination. The growth suppressive effect was due entirely to DAC and not AGI-5198.